Halozyme Therapeutics Inc
HALO67.350USD
+2.240+3.44%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
7.92BMarket Cap
13.79P/E TTM
More Details of Halozyme Therapeutics Inc Company
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme Therapeutics Inc Info
Ticker SymbolHALO
Company nameHalozyme Therapeutics Inc
IPO dateJan 30, 2003
CEOTorley (Helen I)
Number of employees350
Security typeOrdinary Share
Fiscal year-endJan 30
Address12390 El Camino Real
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92130
Phone18587948889
Websitehttps://www.halozyme.com/
Ticker SymbolHALO
IPO dateJan 30, 2003
CEOTorley (Helen I)
Company Executives of Halozyme Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Helen I. Torley
Dr. Helen I. Torley
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
708.72K
--
Mr. Matthew L. (Matt) Posard
Mr. Matthew L. (Matt) Posard
Independent Director
Independent Director
74.04K
+5.96%
Ms. Nicole Labrosse
Ms. Nicole Labrosse
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
22.08K
-30.79%
Ms. Cortney Caudill
Ms. Cortney Caudill
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
7.67K
--
Dr. Mahesh Krishnan, M.D.
Dr. Mahesh Krishnan, M.D.
Independent Director
Independent Director
--
--
Mr. James (Jim) Lang
Mr. James (Jim) Lang
Director
Director
--
--
Ms. Moni Miyashita
Ms. Moni Miyashita
Independent Director
Independent Director
--
--
Mr. Jeffrey W. (Jeff) Henderson
Mr. Jeffrey W. (Jeff) Henderson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Mark Snyder
Mr. Mark Snyder
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Helen I. Torley
Dr. Helen I. Torley
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
708.72K
--
Mr. Matthew L. (Matt) Posard
Mr. Matthew L. (Matt) Posard
Independent Director
Independent Director
74.04K
+5.96%
Ms. Nicole Labrosse
Ms. Nicole Labrosse
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
22.08K
-30.79%
Ms. Cortney Caudill
Ms. Cortney Caudill
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
7.67K
--
Dr. Mahesh Krishnan, M.D.
Dr. Mahesh Krishnan, M.D.
Independent Director
Independent Director
--
--
Mr. James (Jim) Lang
Mr. James (Jim) Lang
Director
Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Royalties
205.64M
63.13%
Sales of proprietary products
46.45M
14.26%
Event-based development and regulatory milestones and other fees
24.50M
7.52%
Sales of bulk rHuPH20
23.27M
7.14%
Sales of device partnered products
11.79M
3.62%
Other
14.07M
4.32%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Royalties
205.64M
63.13%
Sales of proprietary products
46.45M
14.26%
Event-based development and regulatory milestones and other fees
24.50M
7.52%
Sales of bulk rHuPH20
23.27M
7.14%
Sales of device partnered products
11.79M
3.62%
Other
14.07M
4.32%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.86%
BlackRock Institutional Trust Company, N.A.
9.68%
State Street Investment Management (US)
4.27%
Arrowstreet Capital, Limited Partnership
2.80%
UBS Financial Services, Inc.
2.49%
Other
70.90%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.86%
BlackRock Institutional Trust Company, N.A.
9.68%
State Street Investment Management (US)
4.27%
Arrowstreet Capital, Limited Partnership
2.80%
UBS Financial Services, Inc.
2.49%
Other
70.90%
Shareholder Types
Shareholders
Proportion
Investment Advisor
53.00%
Investment Advisor/Hedge Fund
35.16%
Hedge Fund
8.04%
Research Firm
4.70%
Pension Fund
2.37%
Bank and Trust
1.48%
Individual Investor
1.13%
Sovereign Wealth Fund
0.88%
Family Office
0.09%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
1096
120.60M
102.56%
-9.25M
2025Q2
1037
125.48M
107.21%
-10.05M
2025Q1
1043
127.91M
103.79%
-10.64M
2024Q4
999
127.73M
103.64%
-14.45M
2024Q3
953
129.39M
102.16%
-10.33M
2024Q2
905
126.24M
99.18%
-14.91M
2024Q1
870
127.71M
100.45%
-13.70M
2023Q4
850
128.82M
97.51%
-11.71M
2023Q3
836
127.73M
96.80%
-13.97M
2023Q2
838
128.24M
97.33%
-12.36M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
12.22M
10.45%
-584.32K
-4.56%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
11.71M
10.01%
-3.28M
-21.88%
Jun 30, 2025
State Street Investment Management (US)
5.94M
5.07%
-117.96K
-1.95%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
2.54M
2.17%
+1.43M
+127.81%
Jun 30, 2025
UBS Financial Services, Inc.
1.42M
1.21%
+1.12M
+370.46%
Jun 30, 2025
Snyder Capital Management, L.P.
3.40M
2.9%
-276.61K
-7.53%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.43M
2.08%
-736.73K
-23.25%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.01M
1.72%
-14.43K
-0.71%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Future Fund Long/Short ETF
4.62%
First Trust NYSE Arca Biotechnology Index Fund
3.42%
Congress SMid Growth ETF
2.79%
Invesco Biotechnology & Genome ETF
2.61%
Invesco S&P MidCap 400 GARP ETF
2.23%
Janus Henderson Small/Mid Cap Growth Alpha ETF
2.18%
Virtus LifeSci Biotech Products ETF
1.91%
Alpha Architect US Quantitative Value ETF
1.74%
State Street SPDR S&P Biotech ETF
1.69%
First Trust Health Care Alphadex Fund
1.55%
View more
Future Fund Long/Short ETF
Proportion4.62%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.42%
Congress SMid Growth ETF
Proportion2.79%
Invesco Biotechnology & Genome ETF
Proportion2.61%
Invesco S&P MidCap 400 GARP ETF
Proportion2.23%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proportion2.18%
Virtus LifeSci Biotech Products ETF
Proportion1.91%
Alpha Architect US Quantitative Value ETF
Proportion1.74%
State Street SPDR S&P Biotech ETF
Proportion1.69%
First Trust Health Care Alphadex Fund
Proportion1.55%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Halozyme Therapeutics Inc?
The top five shareholders of Halozyme Therapeutics Inc are:
The Vanguard Group, Inc. holds 12.22M shares, accounting for 10.45% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.71M shares, accounting for 10.01% of the total shares.
State Street Investment Management (US) holds 5.94M shares, accounting for 5.07% of the total shares.
Arrowstreet Capital, Limited Partnership holds 2.54M shares, accounting for 2.17% of the total shares.
UBS Financial Services, Inc. holds 1.42M shares, accounting for 1.21% of the total shares.
The Vanguard Group, Inc. holds 12.22M shares, accounting for 10.45% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.71M shares, accounting for 10.01% of the total shares.
State Street Investment Management (US) holds 5.94M shares, accounting for 5.07% of the total shares.
Arrowstreet Capital, Limited Partnership holds 2.54M shares, accounting for 2.17% of the total shares.
UBS Financial Services, Inc. holds 1.42M shares, accounting for 1.21% of the total shares.
What are the top three shareholder types of Halozyme Therapeutics Inc?
The top three shareholder types of Halozyme Therapeutics Inc are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
How many institutions hold shares of Halozyme Therapeutics Inc (HALO)?
As of 2025Q3, 1096 institutions hold shares of Halozyme Therapeutics Inc, with a combined market value of approximately 120.60M, accounting for 102.56% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -4.66%.
What is the biggest source of revenue for Halozyme Therapeutics Inc?
In FY2025Q2, the Royalties business generated the highest revenue for Halozyme Therapeutics Inc, amounting to 205.64M and accounting for 63.13% of total revenue.
